Press Releases

MSCI survey finds 71% of advisers plan to increase their use of active ETFs over the next two years58% say a new active ETF allocation would most likely displace an existing mutual fund45% of respondents expect to broaden their equity allocations beyond their home markets over the next two yearsNearly half are open to accessing less liquid assets through an ETF, but only 16% think private markets are a good fit for the structureNEW YORK, Sept. 14, 2026 /PRNewswire/ -- Active ETFs are firmly in the mainstream and set for further growth, but advisers are putting greater emphasis on value, liquidity and structural fit when deciding which products earn a place in portfolios, according to a surve

Gotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year1Gotistobart demonstrated a median overall survival of 18.5 months compared to 10.0 months with standard-of-care chemotherapy in updated data from stage 1 of the PRESERVE-003 Phase 3 clinical trial, nearly doubling median survival in this patient populationFindings are consistent with gotistobart’s differentiated mechanism of action as an investigational immunomodulator that selectively enhances regulatory T cell depletion through CTL

Global semiconductor revenue surpassed $425bn in 2Q26 reaching another all-time high as the market grew a record 31.4% quarter-over-quarter (QoQ) , according to new research from Omdia. AI demand and strong memory prices continued to be the leading market dynamics, taking total semiconductor revenue for the first half of 2026 to $752 billion. The 31.4% QoQ increase surpassed the previous sequential growth record of 29.2% in 1Q26. Since Omdia began tracking the semiconductor market in 1Q02, only 10 out of 97 quarters have recorded sequential revenue growth above 10%. The last four quarters beginning in 3Q25, have all recorded double-digit sequential growth, with 3Q26 expected to follow the s

Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda ((TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-g

Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by continuing existing cell therapy partnerships while exiting lasme-cel and eti-cel developmentRealignment of the operating model targeting Cellectis cash runway extension into H2 2028Conference call and webcast on September 14: English at 8 a.m. ET, French at 9 a.m. ET NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo

Rapid commissioning operations unlock scarce, very high-resolution imaging capacity as global demand for responsive, tactical space‑based intelligence accelerates BlackSky Technology Inc. (NYSE: BKSY) collected and processed first light imagery from its fifth Gen‑3 satellite in less than 20 hours after liftoff, demonstrating a consistent launch-to-launch pattern of rapid data delivery timelines that significantly outpace the industry standard. Rapid commissioning means customers gain immediate access to mission‑ready, very high‑resolution imagery amid fast-moving operational environments that demand real-time situational awareness to see, understand and act with confidence. This press re

STMicroelectronics introduces automotive image sensorto help scale affordable in-cabin sensing Helps OEMs and Tier 1s bring driver and occupant monitoring to high-volume vehicle platforms with lower system costDelivers 35% higher image sharpness and nearly 60% higher infrared sensitivity than the previous generation in a compact 1.1 MP automotive image sensor Geneva, Switzerland, September 14, 2026 – STMicroelectronics (NYSE:STM), a global semiconductor leader serving customers across the spectrum of electronics applications, introduces ST SafeSense VD56GA, a new 1.1 MP automotive image sensor for infrared in-cabin sensing that helps OEMs and Tier 1 suppliers scale driver and occupant moni

All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapyInvestigators concluded that JNJ-1900 (NBTXR3 may permit clinically meaningful local control using a substantially lower re-irradiation dose than patients’ prior course of radiotherapyEnrollment in the dose-escalation and expansion parts o

Funding Commitment: Signing of binding agreement provides for up to USD1 billion in combined equity commitments from Space42 and Viasat as the initial co-founders of EquatysProgram Progression: Simultaneous signing of agreement to step-up funding accelerates program development of the initial satellite constellation; Scalable constellation’s initial tranche to be awarded upon formation of Equatys with planned appointment of Viasat as prime technology contractorStrategic Differentiation: Equatys intended to offer a foundation for choice and interoperability and provide compelling economic benefits from geographic and spectral efficiencies to participating global, regional and national space o

6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapy AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-m

Longest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. These results were presented today during the Presidential Symposium at the I

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and METResults mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8%SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) muta

Represents a six-month improvement in median progression-free survival versus pembrolizumab plus chemotherapy Daiichi Sankyo and AstraZeneca’s Enhertu is the first HER2 directed medicine to delay disease progression over standard of care in a phase 3 trial in this setting Positive results from the DESTINY-Lung04 phase 3 trial showed Enhertu® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a first-line treatment of patients with unresectable, locally advanced or metastatic HER2 mutant non-squamous non

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLCFindings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 DevelopmentMORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant A

(in U.S. dollars unless otherwise noted)TORONTO, Sept. 13, 2026 /CNW/ -- Franco-Nevada Corporation ("Franco-Nevada" or the "Company") (TSX:FNV) (NYSE:FNV) is pleased to announce that, through a wholly-owned Australian subsidiary, it has entered into an agreement to acquire a A$170 million (approximately $122 million) gross royalty (the "Royalty") from Minerals 260 Limited ("Minerals 260") to further support its development of the Bullabulling Gold Project ("Bullabulling" or the "Project"). Additionally, Franco-Nevada has agreed to subscribe for A$30 million (approximately $22 million) of Minerals 260's ordinary shares (the "Shares") as a lead order in a future equity raise. The Royalty acqui

On September 19 at 5:00 p.m. PT, FF will hold the FF EAI Robotics "Four-Core Full-Stack AI" Ecosystem New Product Series Launch where the Company will focus on launching products of two of its four cores: the EAI Devices core and the Industry Productivity Solutions core.On September 28, FF will hold Part Two of its EAI Robotics "Built in USA" Launch and Business Partner Conference, focused on recruiting upstream partners to drive cooperation in U.S. local manufacturing, supply chain, product certification, and market access.FF welcomes Steven Newton, Senior Advisor to the US General Services Administration and member of the Los Angeles Unified School District Procurement Committee as a senio

Secured a substantial order to supply gas compression systems for the Cloud Connector Pipeline projectAwarded a major order for a modular liquefaction solution supporting Plaquemines LNG facility expansion Awards deepen long-standing strategic collaboration with Venture Global HOUSTON and LONDON, Sept. 13, 2026 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ:BKR) and Venture Global LNG are expanding their long-standing collaboration to advance critical U.S. gas infrastructure. Reinforcing Baker Hughes’ connected capabilities across the natural gas value chain, the company will provide gas compression systems for the Cloud Connector Pipeline project in Louisiana, as well as a modular liquefaction

Company to host webcast tomorrow at 8:00 a.m. EDT Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). Webcast Details Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this li

Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months PD-L1 High Expression Subgroup: Hazard Ratio = 0.58 Summit is Conducting Global Phase III HARMONi-7 Study in Patients with PD-L1 High-Expressing NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab is being presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026

Calvin Klein, Inc., part of PVH Corp. (NYSE:PVH), presented yesterday the Calvin Klein Collection Spring 2027 runway show by Creative Director Veronica Leoni at Terminal Warehouse in New York City. The Collection was a continuation of the exploration of American Minimalism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260912623744/en/Calvin Klein Collection "American Minimalism was a discipline of removal: take away everything that does not carry the work, until only what is necessary remains," said Veronica Leoni, Creative Director of Calvin Klein Collection. "Calvin drew from that and turned it toward the body. I turn it tow